Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / GRFS - FDA approves Grifols' Xembify for primary immunodeficiencies

GRFS - FDA approves Grifols' Xembify for primary immunodeficiencies

Grifols S.A.
  • The FDA has approved Grifols' (NASDAQ:GRFS) Xembify, its new 20% subcutaneous immunoglobulin, used to treat primary immunodeficiencies.
  • More news on: Grifols, S.A., Healthcare stocks news, Stocks on the move,
    • Read more ...
Stock Information
Company Name: Grifols S.A.
Stock Symbol: GRFS
Market: NASDAQ
Website: grifols.com
Menu
GRFS GRFS Quote GRFS Short GRFS News GRFS Articles GRFS Message Board
Get GRFS Alerts

News, Short Squeeze, Breakout and More Instantly...